Medical Device

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a supplier distribution agreement between HealthTab™ Inc., a wholly owned subsidiary, and Abbott, the global healthcare company and diagnostics leader, in Canada.

This agreement allows the Company to distribute in Canada Abbott's Afinion™ 2 and associated tests for diabetes and heart-disease screening in community pharmacies, including HbA1c testing, a critical marker for the screening and management of diabetes.

"Diabetes affects millions of Canadians and early detection is key to avoiding the most serious of impacts of the disease," said Hector Bremner, CEO of Avricore Health. "We're excited to expand our testing capabilities to offer more ways to screen and manage diabetes in community pharmacy."

HealthTab™ continues its work in adding more tests and instruments to the platform, expanding its offering to enhance community pharmacies capabilities with respect to point-of-care testing.

Facts About Diabetes in Canada

According to Diabetes Canada, nearly 30% of Canadians live with diabetes or prediabetes with many undiagnosed. The disease is believed to reduce lifespan by up to 15 years in those affected by significantly contributing to heart attack and stroke risk, as well as other serious chronic disease. Learn more about diabetes in Canada here .

About HealthTab™ + RASTR

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. Results can be printed in-store or accessed securely online.

As part of this direction for HealthTab, the Company developed a revolutionary model for utilizing the system's unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab systems feedback de-identified data through to electronic health records and data management systems via its API capabilities. This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

Contact :

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy .


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Avricore Health

Avricore Health


Keep reading...Show less
How Do Medical Devices Get Approved?

How Do Medical Devices Get Approved?

Life science investors are familiar with the arduous path new drugs must go through to reach the market. But how do medical devices get approved?

In terms of devices, the same rigorous testing and inspection are required from regulatory agencies. The US Food and Drug Administration (FDA) is the agency tasked with reviewing new devices and making amendments to already approved devices.

More specifically, medical device approval is done through the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH looks after the entire regulation process for companies that manufacture, repackage, relabel and import devices to the US.

Keep reading...Show less

Danaher Announces Appointment of Feroz Dewan to Danaher Board

Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Hosts Conference Call for Second-Quarter Earnings

Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022 before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies SG Pte. Ltd ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd ("Infinovo") to manufacture and supply the Continuous Glucose Monitor ("CGM") hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the "Manufacturing Agreement"). The Manufacturing Agreement gives ALRT the exclusive global rights to distribute the Infinovo CGM hardware for the animal health market, providing long-term production and supply. Subject to the satisfaction of all closing conditions it is expected that initial deliveries of product by Infinovo will be made during Q4 of 2022

"Executing the Manufacturing Agreement with Infinovo marks another major milestone in our path to commercialization and profitability," comments Sidney Chan, Chairman and CEO of ALRT. "Our next targeted milestone is securing distribution for the ALRT GluCurve Pet CGM. We have been working with many of the largest global distributors and pharmaceutical companies in animal health, evaluating different distribution opportunities ranging from joint venture partnerships to sales and distribution agreements. We believe we have narrowed in on the right company and right deal structure to best bring value to our shareholders and to those who care for diabetic pets. We hope to announce the details of this pivotal next step in the near future."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO Andrew Morton

Bloom Health Partners CEO Andrew Morton: We're Executing the Plan That We Promised Investors

Bloom Health Partners CEO Andrew Morton: We're Executing The Plan That We Promised Investorsyoutu.be

Keep reading...Show less

Medtronic Board appoints Lidia Fonseca as a new director

Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022 . Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

"We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha , Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the Board with an important dimension and a tremendously valuable perspective as we drive toward our bold ambition to become the global leader in healthcare technology."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×